digoxin
| Product dosage: 0.25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.53 | $48.08 (0%) | 🛒 Add to cart |
| 120 | $0.49 | $64.11 $59.10 (8%) | 🛒 Add to cart |
| 180 | $0.46 | $96.17 $83.14 (14%) | 🛒 Add to cart |
| 270 | $0.43 | $144.25 $117.20 (19%) | 🛒 Add to cart |
| 360 | $0.42
Best per pill | $192.33 $152.26 (21%) | 🛒 Add to cart |
Synonyms | |||
Digoxin, a cardiac glycoside derived from the foxglove plant (Digitalis lanata), represents one of medicine’s oldest and most paradoxically valuable pharmacologic agents. Initially identified in folk medicine for “dropsy” (what we now recognize as congestive heart failure), its modern applications have narrowed but intensified, focusing primarily on rate control in atrial fibrillation and as adjunctive therapy in specific heart failure presentations. What’s fascinating isn’t just its mechanism—potent sodium-potassium ATPase inhibition—but its incredibly narrow therapeutic window, making it one of those drugs where dosing feels more like art than science. I’ve seen seasoned cardiologists still debate loading doses for specific patient phenotypes.
Key Components and Bioavailability Digoxin
The active molecule is straightforward—a steroid nucleus with a lactone ring and sugar moiety—but its behavior in the body is anything but simple. Unlike many modern synthetic drugs, digoxin’s bioavailability ranges from 60-80% in tablet form (higher in elixir), creating significant interpatient variability. The 0.125mg and 0.25mg tablets remain the workhorse formulations, though we occasionally use intravenous preparations in hospital settings for rapid effect.
What most clinicians don’t appreciate until they’ve managed dozens of patients on it: digoxin follows complex pharmacokinetics with substantial tissue binding (particularly cardiac muscle) and renal-dependent elimination. The half-life of 36-48 hours in patients with normal renal function means steady-state takes nearly a week to achieve, something I learned the hard way with my first digoxin toxicity case back in residency.
Mechanism of Action Digoxin: Scientific Substantiation
At its core, digoxin works by inhibiting the sodium-potassium ATPase pump in cardiac myocytes. This creates a seemingly paradoxical effect: increased intracellular sodium leads to reduced calcium extrusion via the sodium-calcium exchanger, resulting in elevated intracellular calcium concentrations. This calcium surge enhances myocardial contractility—the positive inotropic effect we leverage in heart failure.
Simultaneously, digoxin exerts profound electrophysiologic effects through vagal stimulation and direct action on the atrioventricular node. This dual mechanism—improved contractility plus AV nodal suppression—explains why it remains uniquely positioned for patients with heart failure and concomitant atrial fibrillation. The landmark DIG trial from the 1990s demonstrated reduced hospitalizations though not mortality benefit, which actually speaks to its appropriate role as a symptom-modifier rather than disease-curer.
Indications for Use: What is Digoxin Effective For?
Digoxin for Heart Failure with Reduced Ejection Fraction
In contemporary practice, we reserve digoxin for symptomatic HFrEF patients already on guideline-directed medical therapy (beta-blockers, ACE inhibitors, MRAs) who remain symptomatic. It’s not a first-line agent anymore, but for that patient who’s maximized other therapies yet still struggles with fatigue and exertion, adding digoxin can provide meaningful functional improvement.
Digoxin for Atrial Fibrillation Rate Control
This is where I find digoxin most valuable in current practice. For patients with sedentary lifestyles or those who can’t tolerate beta-blockers/calcium channel blockers, digoxin provides reasonable rate control—particularly in those with heart failure where other rate-controlling agents might worsen hemodynamics. The AFFIRM trial subgroup analyses suggested potential concerns about mortality, but in appropriate patients, the benefit-risk profile remains favorable.
Digoxin for Supraventricular Tachycardias
While less common today with advanced ablation techniques, we still occasionally use digoxin for certain SVTs, particularly in infants and children where procedural risks outweigh pharmacologic ones.
Instructions for Use: Dosage and Course of Administration
Dosing digoxin requires considering multiple factors—age, renal function, lean body mass, and concomitant medications. The traditional teaching of “digitalization” with loading doses has largely fallen out of favor except in acute settings.
| Clinical Scenario | Typical Maintenance Dose | Frequency | Special Considerations |
|---|---|---|---|
| Heart Failure (normal renal function) | 0.125 mg | Daily | Lower dose (0.125mg) in elderly > 0.25mg |
| Atrial Fibrillation Rate Control | 0.125-0.25 mg | Daily | Target resting HR < 100 bpm |
| Renal Impairment (CrCl 10-50 mL/min) | 0.125 mg | Every other day or thrice weekly | Level monitoring crucial |
| Advanced Age (>80 years) | 0.125 mg | Daily or less frequently | Increased sensitivity to toxicity |
Therapeutic levels typically range from 0.5-0.9 ng/mL for heart failure and up to 1.2 ng/mL for atrial fibrillation, though I generally prefer the lower end of this spectrum given the mortality signals at higher levels.
Contraindications and Drug Interactions Digoxin
Absolute contraindications include known hypersensitivity (rare), ventricular fibrillation, and amyloid cardiomyopathy. Relative contraindications encompass hypertrophic cardiomyopathy, Wolff-Parkinson-White syndrome (where it can paradoxically accelerate conduction), and significant renal impairment without dose adjustment.
The interaction profile is extensive and clinically significant:
- Amiodarone, verapamil, quinidine: Can increase digoxin levels by 50-100%
- Diuretics: Hypokalemia and hypomagnesemia dramatically increase toxicity risk
- Macrolides, tetracyclines: Gut flora alteration affects bioavailability
- Thyroid disorders: Altered sensitivity and clearance
I once managed a patient whose digoxin level tripled after starting amiodarone despite no change in his digoxin dose—a powerful lesson in anticipating interactions.
Clinical Studies and Evidence Base Digoxin
The Digitalis Investigation Group (DIG) trial remains the foundational study, randomizing 6,800 patients with HFrEF to digoxin or placebo. While all-cause mortality wasn’t significantly different, digoxin reduced hospitalizations for heart failure by 28%—a meaningful endpoint for patients’ quality of life.
For atrial fibrillation, the AFFIRM trial reanalysis raised important questions, suggesting potential increased mortality in certain subgroups. However, more recent meta-analyses, including a 2018 Cochrane review, support its ongoing role for rate control when used judiciously.
What the trials don’t capture well is the individual patient response—I’ve seen some patients derive remarkable symptomatic benefit at levels <0.6 ng/mL, while others show toxicity signs at “therapeutic” levels.
Comparing Digoxin with Similar Products and Choosing Quality
In rate control for AF, digoxin compares interestingly to alternatives:
- Beta-blockers: Better for active patients, but may worsen HF symptoms
- Calcium channel blockers: Contraindicated in decompensated HF
- Digoxin: Preferred in sedentary patients, those with HF, or hypotension
Generic digoxin has consistent bioavailability across manufacturers given its simple chemical structure and longstanding manufacturing standards. The bigger concern isn’t brand selection but appropriate patient selection and monitoring.
Frequently Asked Questions (FAQ) about Digoxin
What monitoring is required for digoxin therapy?
Regular serum level checks (especially with dose changes or interacting drugs), renal function, electrolytes (particularly potassium and magnesium), and clinical assessment for efficacy and toxicity signs.
Can digoxin be used in elderly patients?
Yes, but with caution—reduced renal function, lean body mass, and increased sensitivity necessitate lower doses (typically 0.125mg daily or less frequently).
How long does digoxin take to work?
Initial effects occur within 1-2 hours with peak effect at 6-8 hours, but steady-state and full clinical effect take 5-7 days in patients with normal renal function.
What are the early signs of digoxin toxicity?
Gastrointestinal (nausea, vomiting, anorexia), neurological (visual changes including yellow-green halos, confusion), and cardiac (premature ventricular contractions, bradycardia, heart block).
Conclusion: Validity of Digoxin Use in Clinical Practice
Despite being centuries old, digoxin maintains a specific, though narrowed, role in contemporary cardiology. Its dual mechanism addressing both contractility and rate control creates a unique niche, particularly for the complex patient with heart failure and atrial fibrillation. The key to safe use lies in respecting its narrow therapeutic window, vigilant monitoring, and understanding that it’s an agent for symptom modification rather than mortality reduction.
I remember Mr. Henderson, 78-year-old with persistent AF and chronic kidney disease (eGFR 35), who kept bouncing back with rapid ventricular responses despite maximal beta-blockade. His community cardiologist was ready to refer for AV node ablation, but something about his case didn’t sit right—the ablation would leave him pacemaker-dependent, and his frailty made that a concerning path.
We started low-dose digoxin at 0.125mg every other day, checking levels weekly initially. His wife called two weeks later—first time in months he’d made it through dinner without palpitations. His level settled at 0.7 ng/mL, and he maintained that response for three years until his passing from unrelated causes.
The development of our institutional digoxin protocol was contentious—our pharmacy team wanted restrictive policies given toxicity risks, while our heart failure specialists argued for preserving clinical judgment. We eventually compromised with mandatory pharmacist consultation for initiation and structured nursing education for monitoring signs. The unexpected finding? Our highest utilizers became our palliative care team, who found it invaluable for terminal heart failure patients where symptom control trumped long-term risks.
Just last month, I saw Mrs. Gable for her 6-month follow-up—86 with permanent AF and moderate HFrEF, on digoxin for five years now. Her level remains 0.6 ng/mL, she gardens daily, and her only complaint was that her tomatoes didn’t ripen well this season. Sometimes the oldest tools, when used with appropriate respect for their power, remain remarkably effective.